TipRanks
Sangamo Therapeutics (DE:GBY)
MUNICH:GBY
Germany Market
GBY
Sangamo Therapeutics
RESEARCH TOOLSreports

Sangamo Therapeutics (GBY) Income Statement

4 Followers

Sangamo Therapeutics Income Statement

Last quarter (Q1 2026), Sangamo Therapeutics's total revenue was $1.44M, a decrease of -77.60% from the same quarter last year. In Q1, Sangamo Therapeutics's net income was $-31.00M. See Sangamo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 39.55M$ 57.80M$ 176.23M$ 111.30M$ 110.70M
Gross Profit
$ 31.95M$ 57.80M$ 176.23M$ 99.19M$ 110.70M
Operating Expenses
$ 139.95M$ 161.77M$ 450.24M$ 300.47M$ 294.04M
Depreciation and Amortization
$ 7.60M$ 9.36M$ 22.19M$ 12.11M$ 17.64M
EBITDA
$ -115.90M$ -89.09M$ -96.80M$ -179.74M$ -160.35M
Operating Income
$ -108.00M$ -103.97M$ -274.00M$ -201.28M$ -183.34M
Other Income/Expenses
$ -15.50M$ 5.86M$ 11.10M$ 9.43M$ 5.35M
Pretax Income
$ -123.50M$ -98.11M$ -262.90M$ -191.85M$ -177.99M
Net Income
$ -122.93M$ -97.94M$ -257.83M$ -192.28M$ -178.29M
Per Share Metrics
Basic EPS
$ -0.44$ -0.49$ -1.48$ -1.25$ -1.23
Diluted EPS
$ -0.44$ -0.49$ -1.48$ -1.25$ -1.23
Weighted Average Shares Outstanding
 280.19M 201.70M 174.44M 154.34M 144.57M
Weighted Average Shares Outstanding (Diluted)
 280.19M 201.70M 174.44M 154.34M 144.57M
Currency in USD

Sangamo Therapeutics Earnings and Revenue History